Results 111 to 120 of about 21,114 (141)

Comparison of Two High‐Power Ablation Strategies for Typical Atrial Flutter: Acute and Long‐Term Outcome

open access: yesAnnals of Noninvasive Electrocardiology, Volume 30, Issue 4, July 2025.
ABSTRACT Background Ablation of the cavo‐tricuspid isthmus (CTI) is the standard treatment for typical atrial flutter. High‐power strategies have been described to improve lesion efficacy and durability. Objective To compare the acute success, safety, and long‐term outcomes of two strategies of high‐power CTI ablation using 8‐mm gold‐tip nonirrigated ...
Wael Zaher   +3 more
wiley   +1 more source

Real‐World Health Care Resource Utilization and Costs Associated With First‐Line Dronedarone Versus First‐Line Ablation in Adults With Atrial Fibrillation

open access: yesClinical Cardiology, Volume 48, Issue 6, June 2025.
A retrospective, observational, claims‐based cohort study identified that over 24‐months follow‐up of patients recently diagnosed with AF, a strategy of first‐line dronedarone was associated with similar or lower rates of any outpatient or inpatient visits, and lower total payer costs compared with an ablation‐based approach. ABSTRACT Background Rhythm
Stephen J. Greene   +9 more
wiley   +1 more source

Socio‐economic status and the effect of guideline‐directed medical therapy in the STRONG‐HF study

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1594-1605, June 2025.
Abstract Aims Acute heart failure (AHF) impacts millions globally, with outcomes varying based on socio‐economic status (SES). Methods SES measured by annual household income, years of education and medical insurance coverage. Each patient's income and education level relative to the median or mean, respectively, in the country was calculated, and ...
Albertino Damasceno   +29 more
wiley   +1 more source

Inter‐atrial block as a predictor of adverse outcomes in patients with HFpEF

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 2287-2297, June 2025.
Abstract Aims Inter‐atrial block (IAB), a marker of electrical atrial dysfunction, is associated with an increased risk of atrial fibrillation (AF) and adverse events in various populations. The prognostic impact of IAB in heart failure (HF) with preserved ejection fraction (HFpEF) remains unknown.
Jerremy Weerts   +11 more
wiley   +1 more source

Incidence of atrial fibrillation in patients with an insertable cardiac monitor and symptomatic heart failure

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1693-1702, June 2025.
Atrial fibrillation (AF) was observed in almost half of patients with insertable cardiac monitor and symptomatic heart failure (HF). One‐fourth of the patients had new onset AF and a higher rate of HF events compared with patients without AF. AF incidence was similar in HF patients with preserved versus reduced left ventricular ejection fraction ...
Muhammad Shahzeb Khan   +8 more
wiley   +1 more source

Up‐titration of medication in patients with new‐onset heart failure with and without atrial fibrillation

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1703-1713, June 2025.
Abstract Aims Differences in guideline‐directed medical therapy (GDMT) and clinical outcomes have been observed between heart failure (HF) patients with atrial fibrillation (AF) versus those in sinus rhythm. This study evaluated the effects of up‐titration of HF therapies, consisting of beta‐blockers, angiotensin‐converting‐enzyme inhibitors (ACEis ...
Arietje J.L. Zandijk   +6 more
wiley   +1 more source

Guideline‐directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1861-1871, June 2025.
Abstract Aims Guideline‐directed medical therapy (GDMT) is recommended for all patients with heart failure with reduced ejection fraction (HFrEF). Despite this, little data exist describing GDMT use in diverse, real‐world populations including the use of vasodilators, prescribed primarily to Black populations.
Natalia C. Berry   +4 more
wiley   +1 more source

Pro‐adrenomedullin as an independent predictive biomarker for heart failure in atrial fibrillation and flutter

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1893-1904, June 2025.
Abstract Aims This study aimed to investigate potential biomarkers for predicting incident heart failure (HF) in patients with atrial fibrillation and flutter (AF and AFL), utilizing proteomic data from the UK Biobank Pharma Proteomics Project (UKB‐PPP).
Gaifeng Hu   +8 more
wiley   +1 more source

Severity of tricuspid regurgitation predicts risk of recurrence of atrial fibrillation after pulmonary vein isolation

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1905-1915, June 2025.
Abstract Aims Tricuspid regurgitation (TR) results in right atrial remodelling, thus promoting the formation of a substrate for atrial fibrillation (AF). In turn, AF may cause TR by annulus dilatation. We investigated whether the presence of TR affects the efficacy of pulmonary vein isolation (PVI) for AF. Methods and results In patients undergoing PVI,
Jan Wintrich   +7 more
wiley   +1 more source

Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re‐PHIRE

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 1956-1964, June 2025.
Abstract Aims Despite receiving guideline‐directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH‐LHD) experience higher mortality and hospitalization rates than the general HF population.
Marcin Ufnal   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy